<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181985</url>
  </required_header>
  <id_info>
    <org_study_id>1123.10</org_study_id>
    <nct_id>NCT02181985</nct_id>
  </id_info>
  <brief_title>Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)</brief_title>
  <acronym>ASSENT 3</acronym>
  <official_title>A Phase IIIb, Randomised, Open Label Trial With 3 Parallel Groups: Full Dose TNK-tPA Together With Heparin Sodium, Full Dose TNK-tPA Together With Enoxaparin, and Half Dose TNK-tPA Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction: ASSENT 3 (Assessment of the Safety and Efficacy of New Thrombolytic Regimens)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of ASSENT 3 was to evaluate the safety and efficacy of full dose tenecteplase&#xD;
      with heparin sodium (group A), full dose tenecteplase combined with enoxaparin (group B) and&#xD;
      half dose tenecteplase combined with abciximab and heparin sodium (group C).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <primary_completion_date type="Actual">April 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint: 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemia or in-hospital intracranial hemorrhage (ICH) or in-hospital major bleedings (other than ICH)</measure>
    <time_frame>Up to 30 days after discharge from hospital</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite endpoints: 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemia</measure>
    <time_frame>Up to 30 days after discharge from hospital</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5989</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>TNK-tPA + heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TNK-tPA + enoxaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TNK-tPA + abciximab + heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Full dose TNK-tPA</intervention_name>
    <arm_group_label>TNK-tPA + enoxaparin</arm_group_label>
    <arm_group_label>TNK-tPA + heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Half dose TNK-tPA</intervention_name>
    <arm_group_label>TNK-tPA + abciximab + heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <arm_group_label>TNK-tPA + abciximab + heparin</arm_group_label>
    <arm_group_label>TNK-tPA + heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <arm_group_label>TNK-tPA + enoxaparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab</intervention_name>
    <arm_group_label>TNK-tPA + abciximab + heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Onset of symptoms of AMI within six hours prior to randomisation&#xD;
&#xD;
          -  A twelve-lead electrocardiogram with one of the following: ST-segment elevation ≥ 0.1&#xD;
             millivolt (mV) in two or more limb leads, or ≥ 0.2 mV in two or more contiguous&#xD;
             precordial leads indicative of AMI, or left bundle-branch block&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Informed consent received&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertension defined as blood pressure &gt; 180/110 mm Hg (systolic BP &gt;180 mm Hg and/or&#xD;
             diastolic BP &gt;110 mm Hg) on repeated measurements during current admission prior to&#xD;
             randomization&#xD;
&#xD;
          -  Use of abciximab (ReoPro ®) or other glycoprotein-IIb/IIIa antagonists within the&#xD;
             preceding 7 days&#xD;
&#xD;
          -  Major surgery, biopsy of a parenchymal organ, or significant trauma within 2 months&#xD;
&#xD;
          -  Any minor head trauma and any other trauma occurring after onset of the current&#xD;
             myocardial infarction&#xD;
&#xD;
          -  Any known history of stroke or transient ischemic attack or dementia&#xD;
&#xD;
          -  Any known structural damage of the central nervous system&#xD;
&#xD;
          -  Prolonged cardiopulmonary resuscitation (&gt;10 minutes) in the previous two weeks&#xD;
&#xD;
          -  Current oral anticoagulation&#xD;
&#xD;
          -  Standard unfractionated heparin (heparin sodium) &gt;5000 IU or a subcutaneous dose&#xD;
             within 6 hours of randomization of a therapeutic dose of any low molecular weight&#xD;
             heparin&#xD;
&#xD;
          -  Known thrombocytopenia (prior platelet count below 100000 cells/μl (100 x10**9/l))&#xD;
&#xD;
          -  Known renal insufficiency (prior S-creatinine &gt;2.5 mg% (&gt;220 μmol/l) for men and &gt;2.0&#xD;
             mg% (&gt;175 μmol/l)) for women&#xD;
&#xD;
          -  Pregnancy or lactation, parturition within the previous 30 days. Women of childbearing&#xD;
             potential must have a negative pregnancy test, or use a medically accepted method of&#xD;
             birth control&#xD;
&#xD;
          -  Treatment with an investigational drug under another study protocol in the past 7 days&#xD;
&#xD;
          -  Previous enrollment in this study&#xD;
&#xD;
          -  Known sensitivity to TNK-tPA, tPA, abciximab, heparin or low molecular weight heparin&#xD;
&#xD;
          -  Any other condition that the investigator feels would place the patient at increased&#xD;
             risk if the investigational therapy is initiated&#xD;
&#xD;
          -  Inability to follow protocol and comply with follow-up requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1123/1123.10_U02.1224.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Abciximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

